Clinitech Laboratory Valuation
Is 544220 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 544220 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 544220's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 544220's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 544220?
Other financial metrics that can be useful for relative valuation.
What is 544220's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹205.60m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.2x |
Enterprise Value/EBITDA | 20.9x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 544220's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 9.7x | ||
542918 Gian Life Care | 5.6x | n/a | ₹222.7m |
516110 Family Care Hospitals | 3.6x | n/a | ₹411.6m |
526301 Medinova Diagnostic Services | 18.5x | n/a | ₹385.4m |
514330 One Global Service Provider | 11.1x | n/a | ₹877.4m |
544220 Clinitech Laboratory | 55.4x | n/a | ₹205.6m |
Price-To-Earnings vs Peers: 544220 is expensive based on its Price-To-Earnings Ratio (55.4x) compared to the peer average (9.7x).
Price to Earnings Ratio vs Industry
How does 544220's PE Ratio compare vs other companies in the IN Healthcare Industry?
Price-To-Earnings vs Industry: 544220 is expensive based on its Price-To-Earnings Ratio (55.4x) compared to the Indian Healthcare industry average (48.4x).
Price to Earnings Ratio vs Fair Ratio
What is 544220's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 55.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 544220's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.